Third module of patient partner and researcher training in development
Opportunity for patients and research teams to provide feedback on third imPORTND module ‘Skills for Patient-Oriented Research’
In February 2023, we launched our ‘imPORTND’ platform to offer two online training modules on how to conduct research that is informed by, and most meaningful to, individuals living with neuromuscular disorders. Since the launch we have seen over 100 users access the platform, and we are excited to share that a third training module is currently in development. ‘Skills for Patient-Oriented Research’ includes content on how to develop an effective patient engagement plan, how to share and listen to patient stories, how to work effectively in groups and how to evaluate the project engagement.
Help test the third module
We are currently seeking patients and research team members to test this module and provide feedback on user experience and content relevance. If you or your research team would like to help test the third module, please contact network manager Erin Beattie at <>.
The imPORTND training modules are available for free in both English and French.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.